Amphastar Pharmaceuticals (AMPH) EBIT Margin (2013 - 2026)

Amphastar Pharmaceuticals' EBIT Margin history runs 14 years deep, the most recent figure standing at 7.96% for Q1 2026.

• On a quarterly basis, EBIT Margin fell 1391.0% year-over-year to 7.96% in Q1 2026; TTM through Mar 2026 was 16.2%, a 1045.0% decrease from a year earlier, with the FY2025 full-year figure at 19.5%, down 856.0% from the prior year.
• EBIT Margin retreated to 7.96% in Q1 2026 per AMPH's latest filing, from 19.45% in the prior quarter.
• Across five years, EBIT Margin topped out at 40.25% in Q3 2023 and bottomed at 7.96% in Q1 2026.
• The 5-year median for EBIT Margin is 24.19% (2025), against an average of 23.77%.
• Across the five-year window, EBIT Margin soared 2092 bps in 2023 and plunged 1664 bps in 2025, its largest moves.
• Year by year, EBIT Margin stood at 28.02% in 2022, then increased by 8 bps to 30.31% in 2023, then fell by 20 bps to 24.2% in 2024, then decreased by 20 bps to 19.45% in 2025, then sank by 59 bps to 7.96% in 2026.
• Per Business Quant, the three latest AMPH EBIT Margin figures stand at 7.96% (Q1 2026), 19.45% (Q4 2025), and 13.2% (Q3 2025).